Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
3. DJO Global closes Zimmer/Biomet buys
DJO Global said its subsidiary Encore Medical has closed on the purchase of Zimmer and Biomet assets that the merging companies were unloading to satisfy U.S. anti-trust regulations.
The purchase included Biomet Cobalt bone cement, Optivac cement mixing accessories, the SoftPac pouch and Discovery elbow system for the U.S. marketplace, DJO Global said. Read more
2. Sanuwave updates on PMA trial for Dermapace
Sanuwave Health said it met with the FDA to discuss the progress of a pre-market approval trial of its Dermapace diabetic foot ulcer treatment.
The 130-patient study completed enrollment in November last year and each patient has completed a full-24-week follow-up, the Alpharetta, Ga.-based company said. Read more
1. ConforMIS prices $135m IPO
ConforMIS priced its initial public offering at $15 per share, for total proceeds of $135 million.
The 9-million-share IPO also includes a 1.35-million underwriters over-allotment option, Bedford, Mass.-based ConforMIS said. Read more
The post MassDevice.com +3 | The top 3 medtech stories for July 1, 2015 appeared first on MassDevice.
from MassDevice http://ift.tt/1NwB9va
Cap comentari:
Publica un comentari a l'entrada